Subscribe

Pharmaniaga Berhad (7081.KL)

MYR1.19 -0.01 (-0.83%)
MY KLS Healthcare Medical - Distribution
Address No. 7, Lorong Keluli 1B 40000
Shah Alam, MY
CEO Zulkifli Bin Jafar
Website pharmaniaga.com
IPO 2000-01-03
ISIN MYL7081OO002

Explore sections of this company profile

Description

Pharmaniaga Berhad operates as an investment holding company and an integrated pharmaceutical entity across Malaysia, Indonesia, and international territories. The company organizes its operations into three main segments: Logistics and Distribution, Manufacturing, and its Indonesian business unit. Its core activities encompass the production, distribution, trading, wholesaling, and marketing of a wide array of pharmaceutical and medical products. Additionally, Pharmaniaga is involved in the procurement, sale, and installation of medical and hospital equipment, as well as the trading and wholesaling of consumer goods. The company's offerings also include the manufacturing and sale of generic and over-the-counter medicines, coupled with research and development efforts for pharmaceutical products. It further engages in the production, distribution, trade, and sale of food supplements, alongside the distribution and trading of diagnostic products. Under its RoyalePharma brand, the company also manages community pharmacies. Founded in 1994, Pharmaniaga Berhad is headquartered in Shah Alam, Malaysia, and functions as a subsidiary of Boustead Holdings Berhad.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
MYR1.19 -0.01 (-0.83%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
4M
Beta
0.77
Float Shares
597.76M
Free Float %
9.1%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
-2.04% -4.00% -2.04% -22.58% +0.00% -15.79% -14.29% -31.43% -70.22% -78.76% -49.50%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
1.19
Ratings Trend (MoM) 67% Bullish
Rating 2026-05 Change
Strong Buy 0 0
Buy 2 0
Hold 0 0
Sell 1 0
Strong Sell 0 0
Quality scores
Altman Z-Score
2.44
Grey zone
Piotroski F-Score
3 / 9
Average
MOAT Score
6 / 10
Developing
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
4 / 5
High
ROA Score
4 / 5
High
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
  • ✗
    Revenue growth Medical - Distribution: +5.6%
    +4.5% Q1'26: +11.7% (vs Q1'25)
  • ✗
    EPS growth Medical - Distribution: +4.9%
    -85.4% Q1'26: -76.6% (vs Q1'25)
  • ✓
    FCF margin FCF growth · Medical - Distribution: +37.6%
    +1.4% Q1'26: -2.1% (vs Q1'25)
  • ✗
    EBIT margin Medical - Distribution: +3.0%
    +3.3% ★ Q1'26: +4.9% (vs Q1'25)
  • ✗
    ROIC Medical - Distribution: +5.7%
    +8.6% ★ Q1'26: +14.9% (vs Q1'25)
  • ✗
    Share dilution Medical - Distribution: +0.0%
    +150.7% Q1'26: +355.0% (vs Q1'25)
  • ✗
    Debt / EBITDA Net debt/EBITDA · Medical - Distribution: 0.87×
    4.85× Q1'26: 2.97× (vs Q1'25)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.86) × ERP
WACC = 51% × Ke + 49% × Kd (7.5%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Current price: 1.19
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2016
actual 		Dec 2017
actual 		Dec 2018
actual 		Dec 2019
actual 		Dec 2020
actual 		Dec 2021
actual 		Dec 2022
actual 		Dec 2023
actual 		Dec 2024
actual 		Dec 2025
actual 		Dec 2026
3 Rev. Ana.
3 EPS Ana. 		Dec 2027
3 Rev. Ana.
3 EPS Ana. 		Dec 2028
1 Rev. Ana.
1 EPS Ana.
Revenue
2.33B
est.
2.33B
est.
2.39B
est.
2.82B
est: 2.82B (0.0%)
2.73B
est: 2.81B (-3.2%)
4.82B
est: 4.68B (+3.0%)
3.48B
est: 3.52B (-1.1%)
3.40B
est: 2.88B (+18.3%)
3.76B
est: 3.51B (+7.2%)
3.93B
est: 3.88B (+1.3%)
4.08B
3.94B – 4.18B
+5.1% YoY
4.19B
3.99B – 4.49B
+2.8% YoY
4.47B
4.28B – 4.69B
+6.5% YoY
EBITDA
9.45M
est.
9.44M
est.
9.70M
est.
124.20M
est: 11.43M (+986.9%)
94.43M
est: 11.40M (+728.3%)
335.28M
est: 18.94M (+1,669.8%)
-542.93M
est: 14.25M (-3,909.2%)
-16.32M
est: 11.66M (-240.0%)
288.49M
est: 20.07M (+1,337.6%)
168.94M
est: 22.19M (+661.2%)
23.33M
22.53M – 23.95M
+5.1% YoY
23.99M
22.84M – 25.71M
+2.8% YoY
25.55M
24.49M – 26.81M
+6.5% YoY
EBIT
-2.64M
est.
-2.64M
est.
-2.71M
est.
93.08M
est: -3.19M (+3,014.8%)
69.50M
est: -3.19M (+2,281.4%)
310.40M
est: -5.29M (+5,963.1%)
-570.55M
est: -3.98M (-14,224.1%)
-16.32M
est: -3.26M (-401.0%)
260.93M
est: 1.79M (+14,516.9%)
129.65M
est: 1.97M (+6,467.0%)
2.08M
2.00M – 2.13M
+5.1% YoY
2.13M
2.03M – 2.29M
+2.8% YoY
2.27M
2.18M – 2.39M
+6.5% YoY
Net Income
45.92M
est.
36.24M
est.
37.01M
est.
-149.22M
est: 29.76M (-601.4%)
27.49M
est: 35.43M (-22.4%)
172.15M
est: 65.97M (+160.9%)
-629.92M
est: 40.48M (-1,656.0%)
-80.16M
est: -22.71M (-253.0%)
131.82M
est: 75.19M (+75.3%)
48.51M
est: 43.36M (+11.9%)
61.43M
37.62M – 105.33M
+41.7% YoY
75.89M
40.39M – 135.84M
+23.5% YoY
110.22M
104.27M – 117.28M
+45.2% YoY
SGA
192.13M
est.
191.86M
est.
197.22M
est.
229.51M
est: 232.27M (-1.2%)
227.61M
est: 231.73M (-1.8%)
322.64M
est: 385.08M (-16.2%)
314.72M
est: 289.72M (+8.6%)
328.27M
est: 236.94M (+38.5%)
279.57M
est: 280.08M (-0.2%)
279.51M
est: 309.75M (-9.8%)
325.65M
314.39M – 334.25M
+5.1% YoY
334.85M
318.72M – 358.78M
+2.8% YoY
356.64M
341.84M – 374.23M
+6.5% YoY
EPS
0.03
est.
0.03
est.
0.03
est.
-0.11
est: 0.02 (-632.7%)
0.02
est: 0.02 (-14.6%)
0.13
est: 0.05 (+184.0%)
-0.48
est: 0.03 (-1,808.8%)
-0.06
est: -0.02 (-272.0%)
0.09
est: 0.02 (+339.8%)
0.01
est: 0.01 (+11.7%)
0.02
0.01 – 0.03
+41.7% YoY
0.02
0.01 – 0.04
+23.5% YoY
0.03
0.03 – 0.03
+45.2% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-21 C+ 2/5 1/5 4/5 4/5 1/5 1/5 2/5
2026-05-20 B- 3/5 1/5 4/5 4/5 1/5 2/5 3/5
2026-05-19 B- 3/5 1/5 4/5 4/5 1/5 2/5 3/5
2026-05-18 B- 3/5 1/5 4/5 4/5 1/5 2/5 3/5
2026-05-15 B- 3/5 1/5 4/5 4/5 1/5 2/5 3/5
2026-05-14 B- 3/5 1/5 4/5 4/5 1/5 2/5 3/5
2026-05-13 B- 3/5 1/5 4/5 4/5 1/5 2/5 3/5
2026-05-12 B- 3/5 1/5 4/5 4/5 1/5 2/5 3/5
2026-05-11 B- 3/5 1/5 4/5 4/5 1/5 2/5 3/5
2026-05-08 B 3/5 1/5 4/5 4/5 1/5 3/5 3/5
2026-05-07 B 3/5 1/5 4/5 4/5 1/5 3/5 3/5
2026-05-06 B 3/5 1/5 4/5 4/5 1/5 3/5 3/5
2026-05-05 B 3/5 1/5 4/5 4/5 1/5 3/5 3/5
2026-05-04 B 3/5 1/5 4/5 4/5 1/5 3/5 3/5
2026-04-30 B 3/5 1/5 4/5 4/5 1/5 3/5 3/5
2026-04-29 B 3/5 1/5 4/5 4/5 1/5 3/5 3/5
2026-04-28 B 3/5 1/5 4/5 4/5 1/5 3/5 3/5
2026-04-27 B 3/5 1/5 4/5 4/5 1/5 3/5 3/5
2026-04-24 B 3/5 1/5 4/5 4/5 1/5 3/5 3/5
2026-04-23 B 3/5 1/5 4/5 4/5 1/5 3/5 3/5
2026-04-22 B 3/5 1/5 4/5 4/5 1/5 3/5 3/5
2026-04-21 B 3/5 1/5 4/5 4/5 1/5 3/5 3/5
2026-04-20 B 3/5 1/5 4/5 4/5 1/5 3/5 3/5
2026-04-17 B 3/5 1/5 4/5 4/5 1/5 3/5 3/5
2026-04-16 B 3/5 1/5 4/5 4/5 1/5 3/5 3/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
-64.00M
OE per share TTM
-0.03
Owner's Yield
-3.98%
Maintenance CapEx ratio
41.61%
Maint CapEx / Avg PPE
13.9%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock Held by 4 ETFs in our universe
# ETF Weight Est. AUM exposure TER
1 Dimensional - Emerging Markets ex China Core Equity ETF DEXC 0.01% 17.6K 0.56%
2 Dimensional Emerging Markets Sustainability Core 1 ETF DFSE 0.00% 25.0K 0.44%
3 Dimensional - Emerging Core Equity Market ETF DFAE 0.00% 185.1K 0.29%
4 Dimensional - Emerging Markets Core Equity 2 ETF DFEM 0.00% 50.4K 0.39%

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
37.0K
Shares Outstanding
6.56B

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Zulkifli Bin Jafar Deputy Chief Executive Officer, Managing Director & Director 2M male
Imam Fathorrahman Head of Indonesia Operations 141.0K —
Ahmad Shahredzuan Bin Mohd Shariff Chief Operating Officer 127.5K male
Fazleena Jasin Head of Sustainability — female
Hairul Rizal Samuri Head of Logistics & Distribution — male
Hayat Al-Mazli Yahaya Acting Head of Human Capital Management & Administration — male
Mohd Izwan Ishak Head of Manufacturing — male
Norai'ni Binti Mohamed Ali Chief Financial Officer — female
Syaruzaimi Yusof Company Secretary — male
Wan Intan Idura Wan Ismail Chief Governance Officer & Company Secretary — female
Zulhazri bin Razali Head of Market Expansion Services — male
Erick Arjunan Kereshanan Chief Commercial Officer — male
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend yield history

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Medical - Distribution